CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
December 2014—OvaGene Oncology announced it has entered into a research and development collaboration with Hitachi Chemical Research Center to bring novel mRNA-based signatures to the gynecologic oncology market. The collaboration is founded on Hitachi Chemical’s patented exosome technologies and OvaGene’s research, clinical validation, and translational focus.
The collaboration will undertake the development of blood-based mRNA signatures to guide therapy selection and to monitor therapy response for ovarian cancer. The collaboration will also attempt to identify novel mRNA signatures to diagnose the early initiation of ovarian or endometrial cancer in high-risk women.
OvaGene Oncology, 949-748-6415